Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc., a pioneering biopharmaceutical company based in the United States, focuses on developing innovative therapies for endocrine diseases and cancers. Founded in 2015, Millendo has made significant strides in advancing its proprietary drug candidates, particularly in the areas of adrenal and pituitary disorders. The company’s flagship products, including its lead candidate, are designed to target specific hormonal pathways, offering unique treatment options that address unmet medical needs. With a commitment to scientific excellence, Millendo Therapeutics has positioned itself as a leader in the biopharmaceutical industry, achieving notable milestones in clinical development and regulatory advancements. As it continues to expand its operational footprint, Millendo remains dedicated to transforming the landscape of endocrine therapeutics.
DitchCarbon Score
How does Millendo Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Millendo Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Millendo Therapeutics, Inc.'s reported carbon emissions
Millendo Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a merged entity, Millendo's climate commitments and emissions data may be influenced by its corporate family relationships, but specific details regarding these cascaded initiatives are not available. The company has not established any Science-Based Targets Initiative (SBTi) reduction targets or other industry-standard climate initiatives, which suggests a need for further development in their sustainability strategy. In the context of the biopharmaceutical industry, where climate commitments are increasingly important, Millendo Therapeutics may benefit from adopting measurable targets and transparent reporting to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Millendo Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
